Author

K. Tzelepis

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Cell Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

B. J. P. Huntly· 2 shared G. S. Vassiliou· 2 shared A. Langen· 1 shared A. Liu· 1 shared A. S. M. Magee· 1 shared A. Schuldt· 1 shared B. Zaro· 1 shared C. Lebedenko· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

B. J. P. Huntly

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

RNA binding proteins and glycoRNAs form domains on the cell surface for cell penetrating peptide entry

J. Perr, A. Langen, K. Almahayni, G. Nestola, P. Chai, C. Lebedenko, R. Volk, R. Caldwell, M. Spiekermann, H. Hemberger, N. Bisaria, K. Tzelepis, E. Calo, L. Mockl, B. Zaro, R. A. Flynn

bioRxiv · Sep 4, 2023Cell Biology

Mannose metabolism inhibition sensitizes acute myeloid leukemia cells to cytarabine and FLT3 inhibitor therapy by modulating fatty acid metabolism to drive ferroptotic cell death.

K. Woodley, L. S. Dillingh, G. Giotopoulos, P. Madrigal, K. M. Rattigan, C. Philippe, V. Dembitz, A. S. M. Magee, R. Asby, L. N. van de Lagemaat, C. Mappereley, S. C. James, J. H. Prehn, K. Tzelepis, K. Rouault-Pierre, , P. Gallipoli

This study shows that inhibiting mannose metabolism sensitizes AML cells to cytarabine and FLT3 inhibitors by promoting ferroptotic cell death through fatty acid metabolism changes.

bioRxiv · May 16, 2022Cancer Biology

Identification of SARS-CoV-2 induced pathways reveal drug repurposing strategies

N. Han, W. Hwang, K. Tzelepis, P. Schmerer, E. Yankova, M. MacMahon, W. Lei, N. M. Katritsis, A. Liu, A. Schuldt, R. Harris, K. Chapman, F. McCaughan, F. Weber, T. Kouzarides

The paper identifies 200 approved drugs that target SARS-CoV-2-induced pathways, with 40 in clinical trials, and classifies them into viral replication and immune response mechanisms.

bioRxiv · Aug 24, 2020Pharmacology & Toxicology

KAT7 is a therapeutic vulnerability of MLL-rearranged acute myeloid leukemia

Y. Z. Au, M. Gu, E. De Braekeleer, J. S. L. Yu, S. H. Ong, M. Gozdecka, X. Chen, K. Tzelepis, B. J. P. Huntly, G. S. Vassiliou, K. Yusa

This study identifies KAT7 as a critical therapeutic target in MLL-rearranged AML by showing its role in maintaining acetylation marks and supporting cell proliferation.

bioRxiv · Apr 25, 2020 · PreprintCancer Biology